Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors
Conditions
- Hematological Malignancies
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna